As of 2025-11-19, the EV/EBITDA ratio of Ondine Biomedical Inc (OBI.L) is -2.61. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OBI.L's latest enterprise value is 60.79 mil GBP. OBI.L's TTM EBITDA according to its financial statements is -23.32 mil GBP. Dividing these 2 quantities gives us the above OBI.L EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 4.4x - 6.5x | 5.4x |
| Forward P/E multiples | 4.4x - 6.5x | 5.4x |
| Fair Price | (9.68) - (14.77) | (12.23) |
| Upside | -182.4% - -225.7% | -204.1% |
| Date | EV/EBITDA |
| 2025-11-14 | -4.84 |
| 2025-11-13 | -4.82 |
| 2025-11-12 | -4.82 |
| 2025-11-11 | -5.04 |
| 2025-11-10 | -5.05 |
| 2025-11-07 | -5.06 |
| 2025-11-06 | -5.03 |
| 2025-11-05 | -5.04 |
| 2025-11-04 | -5.36 |
| 2025-11-03 | -5.26 |
| 2025-10-31 | -5.49 |
| 2025-10-30 | -5.57 |
| 2025-10-29 | -5.57 |
| 2025-10-28 | -5.47 |
| 2025-10-27 | -5.37 |
| 2025-10-24 | -5.17 |
| 2025-10-23 | -5.14 |
| 2025-10-22 | -5.14 |
| 2025-10-21 | -5.15 |
| 2025-10-20 | -5.15 |
| 2025-10-17 | -5.17 |
| 2025-10-16 | -5.46 |
| 2025-10-15 | -5.36 |
| 2025-10-14 | -5.36 |
| 2025-10-13 | -5.47 |
| 2025-10-10 | -5.70 |
| 2025-10-09 | -5.68 |
| 2025-10-08 | -5.68 |
| 2025-10-07 | -5.68 |
| 2025-10-06 | -5.69 |
| 2025-10-03 | -5.74 |
| 2025-10-02 | -5.89 |
| 2025-10-01 | -6.00 |
| 2025-09-30 | -6.01 |
| 2025-09-29 | -6.01 |
| 2025-09-26 | -6.02 |
| 2025-09-25 | -6.00 |
| 2025-09-24 | -6.00 |
| 2025-09-23 | -6.22 |
| 2025-09-22 | -6.22 |
| 2025-09-19 | -6.24 |
| 2025-09-18 | -6.42 |
| 2025-09-17 | -6.21 |
| 2025-09-16 | -6.11 |
| 2025-09-15 | -6.35 |
| 2025-09-12 | -6.34 |
| 2025-09-11 | -6.42 |
| 2025-09-10 | -6.43 |
| 2025-09-09 | -6.33 |
| 2025-09-08 | -6.33 |